Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Controlled, Open-label, Phase III Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Based on SNF Molecular Classification

NCT05889871 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05889871
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05889871 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Controlled, Open-label, Phase III Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer Based on SNF Molecular Classification
Lead sponsor
Fudan University
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2023
Completion date
June 1, 2026
Enrollment
916 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hr+/her2-breast cancer